About Lars Ekman
Lars Ekman is a director at Prothena Corp. Public Ltd..
Form D filings name Lars Ekman as a director at Aeovian Pharmaceuticals.
Lars Ekman reports to the SEC as a director of 8 public companies, including Amarin Corp. PLC (AMRN), Ultragenyx Pharmaceutical (RARE) and Spark Therapeutics (ONCE).
Lars Ekman first appears on SEC filings in 2006.
Experience
This experience comes from SEC filings. The years are when the filings name Lars Ekman in the role, so the role may have started earlier or lasted longer.
PC
Prothena Corp. Public Ltd. Co.
Director
2012 – 2026 · Public company (PRTA)
AP
Amarin Corp. PLC
Director
2010 – 2022 · Public company (AMRN)
UI
Ultragenyx Pharmaceutical Inc.
Director
2016 – 2022 · Public company (RARE)
SI
Spark Therapeutics, Inc.
Director
2015 – 2019 · Public company (ONCE)
SI
Sophiris Bio Inc.
Director
2013 – 2019 · Public company (SPHS)
II
Intermune Inc.
Director
2006 – 2014 · Public company (ITMN)
OI
Ocera Therapeutics, Inc.
Director
2013 – 2014 · Public company (OCRX)
AI
ARYx Therapeutics, Inc.
Director
2007 – 2010 · Public company (ARYX)
Key Colleagues at Startups
The people Lars Ekman works with at each company, as listed on that company's latest Form D.
Aeovian Pharmaceuticals, Inc. · Form D, Dec 22, 2025
JK
John Kincaid
Executive officer
YB
Youssef Bennani
Director
TK
Themasap Khan
Director
NR
Nils Regge
Director
DR
Davis Ryman
Executive officer
WG
William Greene
Director
MZ
Micah Zajic
Executive officer
JG
Justin Gover
Director
AH
Allison Hulme
Chief Executive Officer & Director
RG
Richard Gaster
Director